CARM1/HDAC2-IN-1 

CARM1/HDAC2-IN-1 (compound CH-1) is a dual inhibitor against CARM1 and HDAC2, with IC₅₀ values of 3.71 nM and 4.07 nM, respectively. CARM1/HDAC2-IN-1 possesses antitumor activity^[1].

CARM1/HDAC2-IN-1 inhibits proliferation of human prostate cancer cells DU145, RM1, LAPC4, 22RV1 and PC-3, with IC₅₀ values of 0.09 μM , 0.71 μM , 0.68 μM, 0.95 μM and 0.43 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CARM1/HDAC2-IN-1 (i.p.; 0-20 mg/kg, injected every four days for six times) reveals an in vivo dose-dependent antitumor activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

622.76

C₃₅H₄₂N₈O₃

CNCCNCC1=CC=CC(C2=NC(NC3=CC(OCCCCCCC(NO)=O)=CC=C3)=C(C(C4=C5C=CNC5=NC=C4)=N2)C)=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liang S, et al. Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2241118.  [Content Brief]